Livostin

/ Kenvue Hellas Commercial Single Member S.A., Israel

Adults and children: the usual dose is 1 drop of LIVOSTIN eye drops per eye, 2 times daily. The dose may be increased to 1 drop 3 to 4 times daily. Treatment should be continued as long as required for symptom relief.
LIVOSTIN eye drops should be used within one month of the first opening of the bottle. Patients should be instructed to take appropriate measures to avoid contamination of the bottle.

Allergic conjunctivitis (classic and vernalis).

Known hypersensitivity to any ingredient of the preparation. Wearing of soft contact lenses.

Pregnancy and lactation: Should not be used during pregnancy, except if the potential benefit to the mother justifies the potential risk to the fetus. Should not be used during breast-feeding except when the anticipated benefit to the mother is greater than the potential risk to the fetus. Commonplace irritations and infectious conjunctivitis are not indications. Possible local interactions with other eye drops are insufficiently known yet. Combinations with such preparations are therefore best to be avoided.

Throughout this section, adverse reactions are presented. Adverse reactions are adverse events that were considered to be reasonably associated with the use of levocabastine based on the comprehensive assessment of the available adverse event information. A causal relationship with levocabastine cannot be reliably established in individual cases. Further, because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
For full details see prescribing information.

Possible local interactions with other eye drops are insufficiently known yet. Therefore, combination with such preparations are best to be avoided.

Pregnancy: No significant embryotoxic or teratogenic effects were observed in animals (see Non-clinical Information). There are limited postmarketing data on the use of levocabasine eye drops in pregnant women. The risk for humans is unknown. Therefore, LIVOSTIN eye drops should not be used during pregnancy unless the potential benefit to the woman justifies the potential risk to the fetus.
Lactation: Based on determinations of levocabastine concentrations in saliva and breast milk in a nursing woman who received a single oral dose of 0.5 mg levocabastine, it is expected that approximately 0.3% of the total ophthalmically administered dose of levocabastine may be transferred to a nursing infant. However, due to the limited nature of the clinical and experimental data, it is recommended that caution be exercised when administering LIVOSTIN eye drops to nursing women.
Fertility: Animal data have shown no effects on male or female fertility.

Symptoms: Following accidental intake of the contents of the bottle, sedation may occur.
Treatment: In case of accidental ingestion, the patient should be advised to drink a lot of non-alcoholic liquids in order to accelerate the renal elimination of levocabastine.